One antitrust lawyer, not involved in the negotiations, predicted the deal would receive “intense scrutiny” by federal antitrust regulators.
“The type of acquisition that raises the most concern under the antitrust law is when a dominant firm acquires a potential rival,” said the lawyer, David A. Balto, a former policy director of the Federal Trade Commission who now calls himself a public interest antitrust lawyer.
But Steve Cartt, the chief operating officer of Questcor, disagreed. He said Questcor did not have to report the transaction to antitrust regulators because Novartis, the licenser, would retain some manufacturing rights to Synacthen.
The Federal Trade Commission is now proposing new rules to end such exemptions from notification.
So they are "now proposing" new rules. Doubt it's going to be retroactive........
interesting, good take on it. But maybe it's "business as usual" until they show us how to "push/sell" the wonder juice.
ferrari, do you actually "know" something, or is this just speculation? Hint? Settlement perhaps? Thanks!
Personally, I'd pare it down to 50k and put the rest into QCOR. That has a brighter future, plus an extra $500/ qtr divvy. I wish I had your cash DaddyO....I'd burn mine!
Dag, you are a brilliant man. Specialized electricity, right? How come S. Korea is going this route? Size of the country? Smarter than Texans?
Must admit...missed this jump in price, greedy. I'll be there at 1.21 next time.
I love u all...yes, even u md.